Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy
Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy
Background: Cerebral hyperperfusion syndrome (CHS) is a life threatening complication of
 carotid endarterectomy (CEA) and the changes of middle cerebral artery velocity are used to
 predict the occurrence of CHS but the accuracy is limited. In addition, changes of BP
 post-operatively comparing with baseline BP should be a predictive factor of CHS.

 Objective: The investigators aimed to create a predictive index, velocity systolic blood
 pressure index (VSI), for improving the predictive power of Transcranial Doppler monitoring
 regarding CHS.

 Methods: The study design is a diagnostic test, which is an observational analytic clinical
 study. From March 2013 to September 2014, 200 patients will be recruited. Patients will be
 classified according to the CHS occurrence. VSI combined the changes of middle cerebral
 artery velocity and blood pressure crossing CEA and the intra- and post-operative increase
 ratios of middle cerebral artery velocity were calculated. Their prediction power of CHS will
 be compared. Sensitivity, specificity, positive predictive value, negative predictive value
 of them will be calculated. Receiver operating characteristic analysis will be performed.

 Expected Outcomes: Comparing with the commonly used intra-operative and post-operative TCD
 monitoring, VSI may be more useful to select CHS in patients who underwent CEA. As far as the
 investigators know, analysis or studies combining the BP and velocity changes in the
 prediction of CHS have never been performed.
This study is designed as a standard diagnostic test. It is designed to verify the predictive
 power of VSI with CHS, and which is an observational analytic clinical study. The
 investigative parameters of patients will be collected prospectively by the designed case
 report form. According to the incidence of CHS, the estimated enrollment amount is set as
 200. Patients will be recruited by the inclusion and exclusion criteria below. All the
 patients included will accept the standard CEA surgery treatment in the department of
 vascular surgery of PUMCH. MCAV and systolic BP data will be recorded cross CEA.
 Post-operatively the CHS patients will be identified according to the golden standard. The
 golden standard is the clinical diagnose of CHS (the detailed diagnostic criteria will be
 stated in the methodology part). The TCD operator is blind to the patients. The predictive
 power of VSI will be identified by the sensitivity, specificity, positive predictive value,
 negative predictive value and ROC plot comparing with the golden standard. The study start
 date is March 2013, the estimated study completion date is December 2014 and the primary
 completion date is September 2014 (final data collection date for primary outcome measure).
Inclusion Criteria:

 1. Age from 30 to 85 years;

 2. Had a middle-grade symptomatic carotid stenosis (more than 50%) or a high-grade
 asymptomatic carotid stenosis (more than 70%);

 3. Underwent CEA 30 days after the last ischemic cerebrovascular event in the case of
 symptomatic carotid stenosis;

 4. Signed the ethical information consent form

 5. Underwent TCD study intraoperative and immediately after CEA;

 6. The degree of carotid stenosis will be assessed by CT angiography or cerebral digital
 subtraction angiography (DSA). (The method document came from the North American
 Symptomatic Carotid Endarterectomy Trial study.)

 Exclusion Criteria:

 1. Emergency CEA within 30 days of stroke onset in the case of symptomatic carotid
 stenosis;

 2. No temporal windows to measure the MCAV.

 3. Restenosis after CEA or CAS

 4. Stenosis caused by non-atherosclerotic diseases

 5. Combined severe systematic diseases that markedly decrease the life cycle

 6. Allergy to medicines of the study such as Aspirin or Statin

 7. Refuse to sign the ethical information consent form